Halozyme appoints 30-year finance veteran Darren Snellgrove as CFO effective June 8
HALO•Halozyme named Darren Snellgrove as Chief Financial Officer effective June 8, 2026, to lead financial operations, capital allocation, corporate development and investor relations. He brings over 30 years of finance leadership experience, including directing investor relations and serving as CFO for a $50 billion-revenue pharmaceuticals sector at Johnson & Johnson.
1. Appointment Details
Halozyme announced that Darren Snellgrove will assume the role of Chief Financial Officer on June 8, 2026. In this capacity, he will oversee the company’s financial operations, capital allocation, corporate development and investor relations, reporting directly to President and CEO Helen Torley.
2. Snellgrove’s Professional Background
Snellgrove brings more than 30 years of financial leadership in the biopharmaceutical and medtech sectors. His most recent role led investor relations at Johnson & Johnson, where he reshaped corporate messaging and strengthened analyst and shareholder engagement, and he previously served as CFO for J&J’s $50 billion-revenue pharmaceuticals sector.
3. Strategic Implications for Halozyme
His appointment is expected to accelerate Halozyme’s value-creation initiatives by enhancing financial strategy and investor engagement. With expertise in large-scale portfolio investments, restructuring and business development, Snellgrove is positioned to support the expansion of Halozyme’s drug-delivery technology portfolio and royalty-stream optimization.
